ArticleFrontiers in pharmacology2026
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis.
Yitian Lang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.